BIOKIN PHARMACEUTICAL(SH:688506) Xin Lang Cai Jing·2025-09-02 02:59Group 1 - The core viewpoint of the news is that Baili Tianheng's stock price increased by 5.39% to 365.70 CNY per share, with a trading volume of 386 million CNY and a turnover rate of 1.07%, resulting in a total market capitalization of 146.646 billion CNY [1] - Baili Tianheng Pharmaceutical Co., Ltd. is located in Chengdu, Sichuan Province, and was established on August 17, 2006, with its listing date on January 6, 2023. The company's main business involves the research, production, and sales of pharmaceuticals [1] - The revenue composition of Baili Tianheng shows that 99.57% is recognized at a specific point in time, while 0.43% is recognized over a specific period [1] Group 2 - From the perspective of major fund holdings, one fund under Guotai Fund has a significant position in Baili Tianheng. The Guotai SSE STAR Market Comprehensive ETF (589630) held 63,200 shares in the second quarter, accounting for 1.64% of the fund's net value, making it the sixth-largest holding [2] - The Guotai SSE STAR Market Comprehensive ETF (589630) has a current scale of 1.141 billion CNY and has achieved a return of 30.91% since its inception on March 4, 2025 [2] Group 3 - The fund managers of the Guotai SSE STAR Market Comprehensive ETF (589630) are Ma Yiwen and Liu Fangyuan. Ma Yiwen has a cumulative tenure of 2 years and 27 days, with the fund's total asset size at 6.894 billion CNY, achieving a best return of 86.18% and a worst return of 2.44% during the tenure [3] - Liu Fangyuan has a cumulative tenure of 145 days, with the fund's total asset size at 2.677 billion CNY, achieving a best return of 43.15% and a worst return of 17.78% during the tenure [3]